[company_age]3.0[/company_age][employees]11-50 employees[/employees][funding]seed[/funding][description]Ainnocence is a leading AI-powered drug discovery company that utilizes generative AI to accelerate molecule discovery and reduce R&D costs by over 50%. Their platform offers one of the most accurate and efficient molecule design systems available, backed by billions of proprietary datasets. Ainnocence's technology provides larger screening spaces and delivers results 10,000 times faster than competitors, without the need for 3D structure modeling. This translates to tremendous computational power and unparalleled value for every phase of small and large molecule drug discovery projects, from hit identification to lead optimization. 

Ainnocence's unique approach sets them apart from traditional drug discovery companies. Their AI-driven platform eliminates the reliance on 3D modeling and docking, a major industry bottleneck, resulting in rapid results and significant cost savings. Additionally, Ainnocence offers de novo creation of novel small and large molecules through generative AI, further streamlining the drug discovery process. 

Ainnocence's technology has been validated through laboratory studies and endorsements from leading pharmaceutical and biotechnology companies, along with top-tier research institutes. Their platform significantly reduces the costs and risks associated with drug discovery, bringing the industry closer to solutions for some of humanity's most challenging diseases.[/description][ps]AI-driven drug discovery platform, antibody de novo design, humanization, affinity maturation, small molecule design, virtual screening, lead optimization[/ps]